Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an announcement.
Paradigm Biopharmaceuticals Limited has announced the issuance of 6,066,476 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX). This move is part of the company’s strategic efforts to enhance its financial flexibility and support its ongoing projects. The issuance of these securities is expected to strengthen Paradigm’s market position and provide additional resources to further its research and development initiatives.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of therapies for inflammatory diseases. The company is known for its efforts in advancing treatments that address unmet medical needs, particularly in the areas of osteoarthritis and other musculoskeletal disorders.
YTD Price Performance: -17.33%
Average Trading Volume: 800,750
Technical Sentiment Signal: Sell
Current Market Cap: A$123.2M
Learn more about PAR stock on TipRanks’ Stock Analysis page.